GHK-Cu Peptide Benefits: What the Science Actually Shows

A copper-binding tripeptide that weighs less than a small protein fragment, GHK-Cu (glycine-histidine-lysine copper) has accumulated one of the most compelling bodies of preclinical and clinical evidence of any peptide in the longevity toolkit. First isolated from human plasma in 1973 by Loren Pickart, it was initially characterised for its ability to stimulate liver cell growth. What followed over the next five decades was a cascade of findings that repositioned GHK-Cu not as a niche cosmetic ingredient but as a systemic signalling molecule with broad biological reach: collagen synthesis, wound healing, neuroregeneration, anti-inflammatory gene regulation, and hair follicle activation. Understanding the GHK-Cu peptide benefits requires navigating that full body of evidence, distinguishing what is established from what is promising, and clarifying where the route of administration changes everything.

GHK-Cu occurs naturally in human blood plasma at concentrations around 200 nanograms per millilitre in young adults, but those levels fall sharply with age, dropping to roughly 80 nanograms per millilitre by the seventh decade [1]. That decline coincides with the well-documented slowdown in tissue repair, collagen turnover, and immune modulation that characterises biological ageing. Whether replenishing GHK-Cu can meaningfully reverse those deficits is the central clinical question, and the answer, as with most longevity interventions, is nuanced.

The Biology of GHK-Cu: How a Tripeptide Becomes a Master Regulator

GHK-Cu is not simply a structural compound. It operates as a signalling molecule, binding to cell surface receptors and transporting copper into cells, where copper acts as a cofactor for enzymes involved in collagen cross-linking, antioxidant defence, and energy metabolism. The analogy is useful: if copper is the key, GHK is the lockpick that gets it into the right door at the right time. Without the peptide chaperone, copper in free ionic form is poorly bioavailable and potentially cytotoxic, generating reactive oxygen species through Fenton-like chemistry. Bound to GHK, it becomes a precision tool.

The biological range of GHK-Cu extends well beyond copper transport. Loren Pickart and colleagues catalogued its effects on gene expression using early microarray technology, finding that GHK-Cu modulates over 4,000 human genes, activating genes associated with tissue remodelling and repair while suppressing those linked to inflammation, cancer progression, and neurodegeneration [2]. This is not a molecule that nudges a single pathway. It behaves more like a conductor restoring a disordered orchestra to something approaching its youthful arrangement.

At the cellular level, GHK-Cu activates the ubiquitin-proteasome system, the cell's internal recycling machinery that clears misfolded or damaged proteins. It also upregulates superoxide dismutase and catalase, two of the cell's primary antioxidant enzymes, while downregulating nuclear factor kappa B (NF-kB), the master transcription factor that drives chronic inflammatory gene expression [3]. These mechanisms converge on a picture of a molecule that does not merely accelerate one repair process but recalibrates the cellular environment toward regeneration.

GHK-Cu modulates over 4,000 human genes, activating tissue remodelling pathways while suppressing those linked to inflammation and neurodegeneration — a regulatory breadth unusual for a molecule of its size.

Wound Healing and Skin Repair: The Most Established Domain

The wound healing evidence for GHK-Cu is the most mature in the literature, supported by decades of in vitro, animal, and human studies. Skin repair requires a precisely timed choreography of events: haemostasis, inflammation, proliferation, and remodelling. GHK-Cu appears to accelerate this sequence at multiple stages simultaneously.

In keratinocytes (the dominant cell type of the skin's outer layer) and dermal fibroblasts (the connective tissue cells responsible for collagen production), GHK-Cu increases cell proliferation and migration, the two processes that physically close a wound [2]. It stimulates the production of extracellular matrix components including fibronectin and glycosaminoglycans, the molecular scaffolding into which new collagen is deposited. Animal studies in rats have shown significantly faster wound closure with topical GHK-Cu application compared to controls, with histological analyses confirming improved collagen fibre organisation rather than the disorganised scarring typical of unassisted repair [2].

In human clinical trials examining chronic wounds, including venous leg ulcers that resist standard treatment, copper peptide-containing formulations have demonstrated measurable improvements in wound closure rates. A controlled trial found that topical GHK-Cu application accelerated the healing of full-thickness dermal wounds and reduced the inflammatory phase, shortening the period during which the wound is most vulnerable to infection [2]. The effect is not cosmetic. Faster inflammatory resolution means less scarring, less secondary infection risk, and restoration of functional tissue architecture.

For skin ageing specifically, the mechanism becomes even more relevant. Photoaged skin is characterised by fragmented collagen networks, a phenomenon sometimes described as the skin losing its internal scaffolding. GHK-Cu has been shown to stimulate collagen I, III, and IV synthesis in human fibroblast cultures, while simultaneously activating matrix metalloproteinases (MMPs) that clear damaged collagen fragments before new deposition begins [4]. This dual action, clearing the old and building the new, distinguishes it from compounds that merely stimulate collagen production without addressing the debris that accumulates in aged dermis. Clinical studies with topical GHK-Cu creams have confirmed statistically significant improvements in skin laxity, density, and thickness in middle-aged participants [5].

Collagen Synthesis: The Structural Argument for Systemic Effects

Collagen is not just a skin protein. It constitutes approximately 30 percent of total body protein and forms the structural backbone of tendons, ligaments, cartilage, bone matrix, blood vessel walls, and gut lining. The implications of GHK-Cu's collagen-stimulating effects therefore extend well beyond dermatology.

The peptide's influence on collagen synthesis operates through fibroblast activation and through the direct modulation of key regulatory genes. GHK-Cu upregulates TGF-beta1 (transforming growth factor beta-1), a growth factor that instructs fibroblasts to produce collagen, while also increasing the expression of SPARC (secreted protein acidic and rich in cysteine), a matricellular protein that organises newly synthesised collagen into functional fibres [4]. The result is not simply more collagen, but better-organised collagen, the architectural difference between rope and a pile of threads.

Animal studies examining tendon repair have found that GHK-Cu injected locally into damaged Achilles tendons produced histologically superior tendon tissue compared to controls, with improved tensile strength and faster return to normal collagen fibre alignment [2]. For practitioners and patients in the longevity space, this has practical implications: the same age-related decline in GHK-Cu that impairs skin repair also impairs connective tissue maintenance throughout the body, and the same signalling pathways that topical application targets in skin may be accessible systemically via injection, though the evidence for systemic injectable use remains primarily preclinical.

Collagen constitutes roughly 30 percent of total body protein. GHK-Cu does not simply stimulate its production — it helps organise the architecture that makes collagen structurally functional.

Anti-Inflammatory Signalling: Resetting the Chronic Inflammation Dial

Chronic low-grade inflammation, now widely referred to as "inflammaging" in geroscience literature, is a defining feature of biological ageing and a driver of virtually every age-related disease, from atherosclerosis to neurodegeneration. GHK-Cu's anti-inflammatory profile is one of its most pharmacologically interesting properties.

The primary mechanism involves NF-kB suppression. NF-kB is a transcription factor that sits at the hub of inflammatory gene regulation, coordinating the production of cytokines including TNF-alpha, IL-1beta, and IL-6, the signalling proteins that sustain chronic inflammation. GHK-Cu has been shown in multiple cell culture and animal models to reduce NF-kB activation, thereby lowering the downstream expression of these pro-inflammatory mediators [3]. In lung cell models specifically, GHK-Cu significantly attenuated inflammation-driven gene expression patterns associated with pulmonary fibrosis, a condition in which chronic inflammatory signalling leads to irreversible scarring of lung tissue [6].

A landmark 2012 analysis by Pickart and Margolina used gene expression databases to compare GHK-Cu's transcriptional effects against a library of known anti-inflammatory and anti-cancer drug signatures [2]. The pattern of gene regulation produced by GHK-Cu was found to be remarkably similar to that of multiple established anti-inflammatory agents, suggesting the peptide activates the same regulatory networks through its own distinct mechanism. This kind of systems-level evidence is rare for peptide compounds and lends mechanistic credibility to the clinical observations.

GHK-Cu also modulates the inflammatory response through its effects on macrophage polarisation. Macrophages are immune cells that can adopt either pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes depending on signals from their environment. Evidence suggests GHK-Cu promotes a shift toward M2 polarisation, which favours tissue repair over inflammatory amplification [3]. In the context of ageing, where chronic M1 macrophage activity is thought to sustain inflammaging, this shift could have meaningful consequences for long-term tissue health. The anti-inflammatory evidence provides the mechanistic bridge to the next domain: brain and nerve repair.

Neuroregeneration: Emerging Evidence for Brain and Nerve Repair

The brain is metabolically expensive, generates enormous oxidative stress, and is exquisitely sensitive to inflammatory insult. It is also, under normal circumstances, poorly equipped for repair. The neuroprotective potential of GHK-Cu is therefore one of the most scientifically compelling and clinically urgent areas of its emerging research profile.

GHK-Cu crosses the blood-brain barrier, a selective membrane that excludes most large molecules from the central nervous system. Its small size (molecular weight approximately 340 daltons) facilitates this transit, and once inside, it appears to exert several neuroprotective effects simultaneously. In animal models of spinal cord injury, GHK-Cu administration reduced secondary neuronal death (the cascade of inflammation-driven cell loss that follows the initial trauma), preserved myelinated nerve fibre integrity, and improved functional recovery scores compared to saline controls [2].

The mechanisms are multiple. GHK-Cu increases nerve growth factor (NGF) expression in neural tissue, a signalling protein essential for the survival and maintenance of cholinergic neurons, precisely the neurons most affected in Alzheimer's disease [2]. It also upregulates brain-derived neurotrophic factor (BDNF), which supports synaptic plasticity and the formation of new neural connections. Think of BDNF as the fertiliser for the brain's garden: without it, existing connections weaken and new growth stalls.

In the context of neurodegeneration, GHK-Cu's gene expression profile is particularly striking. Pickart's analysis identified a substantial overlap between GHK-Cu-responsive genes and those dysregulated in Alzheimer's disease, with GHK-Cu tending to normalise the expression of genes that are aberrantly up- or down-regulated in AD brain tissue [2]. This does not constitute clinical evidence of efficacy in Alzheimer's, but it provides a mechanistic rationale for further investigation that is grounded in real transcriptomic data rather than speculation.

Copper dysregulation itself is increasingly recognised as a contributing factor in several neurodegenerative conditions. In Alzheimer's disease, copper accumulates abnormally around amyloid plaques, and its redox activity (the ability to donate and accept electrons) contributes to the oxidative damage that kills neurons [7]. GHK's copper-chaperoning function may help restore normal copper partitioning in neural tissue, sequestering free ionic copper before it causes oxidative harm. This represents an intersection between GHK-Cu's two properties: its peptide signalling effects and its copper chemistry. The hair growth evidence follows a similarly multi-mechanistic path.

Hair Growth: Follicle Biology and the Copper Peptide Effect

Hair follicles are among the most metabolically active structures in the human body, cycling through growth (anagen), regression (catagen), and rest (telogen) phases in a precisely regulated sequence. That regulation depends on a complex array of growth factors, signalling molecules, and the structural integrity of the dermal papilla, the cluster of specialised cells at the follicle base that controls the hair growth cycle. GHK-Cu influences this biology at several points.

Animal studies have demonstrated that topical GHK-Cu application increases follicle size, stimulates entry into the anagen (growth) phase, and increases the diameter of hair shafts [2]. The mechanism involves upregulation of vascular endothelial growth factor (VEGF) in the scalp dermis, which improves blood supply to follicles, and stimulation of keratinocyte growth factor (KGF), which directly promotes follicle proliferation. GHK-Cu also inhibits TGF-beta2, a signalling protein that promotes follicle miniaturisation, the process through which androgenic alopecia (pattern baldness) progressively shrinks follicles until they can no longer produce visible hair [2].

A controlled clinical study found that a topical GHK-Cu solution applied daily for 12 weeks produced a statistically significant increase in hair density and a reduction in hair loss in participants with androgenic alopecia, with effects comparable to 5 percent minoxidil in some measures [8]. The mechanisms differ fundamentally from minoxidil (which primarily acts as a vasodilator) and from finasteride (which inhibits the conversion of testosterone to dihydrotestosterone). GHK-Cu appears to act more directly on follicle biology, which raises the possibility that it may be synergistic rather than merely redundant with existing treatments. For readers interested in a comprehensive approach to hair loss, Topical Rapamycin+ for Hair represents another evidence-based intervention operating through distinct, potentially complementary mechanisms.

GHK-Cu inhibits TGF-beta2, the signalling protein that miniaturises hair follicles in androgenic alopecia — a mechanism distinct from both minoxidil and finasteride, raising genuine synergy potential.

Epigenetic Resetting: GHK-Cu and the Ageing Genome

One of the most intellectually provocative findings in GHK-Cu research involves its relationship to the epigenome, the system of chemical marks on DNA and histone proteins that regulate which genes are expressed without altering the underlying sequence. Biological ageing is now understood to involve progressive epigenetic dysregulation, captured quantitatively by methylation clocks like Horvath's that can estimate biological age from blood samples.

Analysis of GHK-Cu's transcriptional effects against databases of age-associated gene expression changes has found that GHK-Cu consistently reverses the direction of age-related gene expression alterations, upregulating genes that decline with age and downregulating those that increase [3]. In other words, GHK-Cu's gene expression signature resembles that of younger tissue. This does not confirm that GHK-Cu resets biological age in the strict epigenetic clock sense, but it provides a molecular basis for the clinically observed effects on tissue quality and repair capacity.

The peptide has also been shown to activate genes involved in DNA repair, specifically those encoding enzymes that correct double-strand DNA breaks, one of the primary forms of genomic damage that accumulates with age and contributes to cellular senescence [3]. Cellular senescence, the state in which cells stop dividing but remain metabolically active and secrete inflammatory signals (the senescence-associated secretory phenotype, or SASP), is a well-established driver of tissue ageing. A molecule that reduces DNA damage accumulation would, by extension, reduce the rate of senescent cell accumulation, making GHK-Cu a potential indirect senolytic-adjacent agent, not because it clears senescent cells but because it reduces their formation rate.

This epigenetic dimension connects GHK-Cu to the broader longevity pharmacology landscape and suggests it may complement interventions like Cellular Renewal Stack, which targets senescence and cellular health through parallel but distinct mechanisms.

Topical Versus Injectable: Why the Route of Administration Changes Everything

The distinction between topical and injectable GHK-Cu is not a minor clinical footnote. It determines which tissues are exposed, at what concentrations, and through what mechanisms. Most of the human clinical evidence for GHK-Cu, particularly in wound healing and hair growth, derives from topical application, where the peptide acts locally on skin, follicles, and superficial dermal tissue. Injectable GHK-Cu operates on a fundamentally different premise: systemic distribution via the bloodstream to reach tissues that topical application cannot access, including the brain, lungs, joints, and visceral organs.

Topical GHK-Cu penetrates the epidermis and reaches the dermis effectively. Small peptides below 500 daltons in molecular weight can cross the stratum corneum (the outer skin barrier) through intercellular lipid channels, and GHK-Cu's molecular weight of approximately 340 daltons places it firmly in the permeable range [5]. The concentrations achievable in skin with topical application are meaningful: formulations typically contain GHK-Cu at 0.1 to 2 percent, delivering nanomolar to micromolar concentrations at the dermal fibroblast level, sufficient to activate the signalling pathways documented in cell culture studies.

Injectable GHK-Cu, typically administered subcutaneously or intramuscularly, achieves plasma distribution and can reach tissues inaccessible to topical routes. The preclinical evidence for systemic effects (neuroregeneration, lung protection, systemic anti-inflammation) comes primarily from injection-based animal studies, where the compound was delivered at doses that produced measurable plasma concentrations. Translating those findings to human clinical practice requires caution: the absence of large-scale randomised controlled trials for injectable GHK-Cu in humans means that dosing, pharmacokinetics, and long-term safety profiles are not yet established with the rigour that would satisfy regulatory standards.

What is known from animal pharmacokinetic studies is that GHK-Cu has a short plasma half-life, typically under 30 minutes, which means that sustained elevation of plasma levels requires either frequent dosing or sustained-release formulations [2]. The brief half-life also limits concerns about accumulation toxicity, and GHK-Cu has demonstrated a consistently benign safety profile across studies, with no evidence of mutagenicity, carcinogenicity, or significant adverse effects at pharmacologically relevant doses.

Antioxidant Defence and Mitochondrial Health

Mitochondria, the cellular organelles that generate ATP through oxidative phosphorylation, are both the primary source of reactive oxygen species (ROS) and among the first casualties of their accumulation. As cells age, mitochondrial efficiency declines, ROS production increases, and the resulting oxidative stress damages lipids, proteins, and DNA in a self-amplifying cycle. GHK-Cu addresses this at multiple points.

Copper-dependent superoxide dismutase (SOD), specifically the cytoplasmic form SOD1 and the mitochondrial form SOD2, are the cell's first-line defences against superoxide radicals, the most abundant ROS generated by mitochondrial electron transport. GHK-Cu stimulates SOD expression, increasing the cell's capacity to convert toxic superoxide into less reactive hydrogen peroxide, which is then neutralised by catalase and glutathione peroxidase [3]. This enzymatic chain is the cell's version of a multi-stage water filtration system: each step converts a more dangerous species into a less reactive one.

Beyond antioxidant enzyme induction, GHK-Cu has been shown to reduce mitochondrial membrane permeability transition, the catastrophic loss of mitochondrial membrane integrity that triggers cell death pathways including apoptosis and necrosis [2]. Preserving mitochondrial membrane integrity under stress conditions is one of the key determinants of cell survival during ischaemia-reperfusion injury, the damage that occurs when blood flow is restored to oxygen-deprived tissue (as in cardiac events or stroke). Animal studies have found that pre-treatment with GHK-Cu reduces the area of tissue death following experimentally induced myocardial infarction, an effect attributed partly to this mitochondrial protection mechanism [2].

Lung and Organ Protection: Evidence from Preclinical Models

GHK-Cu's anti-fibrotic and anti-inflammatory properties have drawn particular attention in pulmonary medicine. Pulmonary fibrosis involves the progressive replacement of functional lung tissue with scar collagen, driven by TGF-beta1-mediated fibroblast activation. GHK-Cu presents a paradox here: it stimulates collagen synthesis in wound-healing contexts, yet appears to suppress pathological fibrosis in lung models. The resolution lies in context-specificity. GHK-Cu stimulates organised, remodelling-appropriate collagen deposition while simultaneously activating MMPs that prevent abnormal collagen accumulation [6]. In fibrosis, it appears the anti-fibrotic gene regulation outweighs the pro-synthesis effects, particularly because GHK-Cu also suppresses TGF-beta1 signalling in the specific context of fibroblast-to-myofibroblast transformation, the cellular switch that drives irreversible fibrosis.

In a gene expression study examining normal human lung tissue versus fibrotic lung tissue, GHK-Cu was found to normalise the expression of over 100 genes dysregulated in fibrosis, including those controlling extracellular matrix remodelling, inflammatory signalling, and cell death pathways [6]. These findings have not yet been translated into human clinical trials for pulmonary fibrosis, but they establish GHK-Cu as a molecule with a credible biological rationale for further investigation in this devastating condition.

Similar preclinical evidence exists for kidney protection. In animal models of nephrotoxic injury, GHK-Cu administration reduced tubular cell death, preserved glomerular filtration architecture, and attenuated the inflammatory infiltrate that drives chronic kidney disease progression [2]. Again, these are preclinical findings, but they reinforce the picture of a systemically protective molecule operating across multiple organ systems through conserved anti-inflammatory and antioxidant mechanisms.

Cancer Biology: A Nuanced Relationship

GHK-Cu's relationship to cancer biology requires careful handling because it involves both tumour-suppressive and theoretically tumour-permissive properties. On the suppressive side, GHK-Cu has been shown to upregulate tumour suppressor genes and downregulate genes associated with metastatic invasion, including those encoding matrix metalloproteinases that facilitate cancer cell migration through tissue [3]. Gene expression analyses have found that GHK-Cu normalises the expression of cancer-associated genes across multiple cancer types, suggesting a broad anti-proliferative transcriptional signature.

The theoretical concern arises from GHK-Cu's pro-proliferative effects in wound healing: the same growth factor stimulation that drives fibroblast proliferation and keratinocyte migration could, in principle, support the growth of existing malignant cells. The evidence from cell culture studies, however, has generally found the opposite: GHK-Cu inhibits proliferation in cancer cell lines while stimulating it in normal cells, a selectivity attributed to the different receptor expression profiles and intracellular signalling contexts of malignant versus normal cells [3]. This does not constitute clinical reassurance that GHK-Cu is safe in patients with active malignancy, and caution remains appropriate in that population until prospective data are available.

Safety Profile and Current Limitations of Evidence

GHK-Cu has been studied for over five decades without emergence of significant toxicity signals. Acute and chronic toxicity studies in rodents have found no mutagenic, carcinogenic, or teratogenic effects at doses far exceeding typical pharmacological applications [2]. The compound is also biodegradable, as it is simply a tripeptide and copper complex that can be metabolised by normal proteolytic pathways. These safety characteristics are one reason GHK-Cu has been used in cosmetic formulations for decades without regulatory concern.

The limitations of the evidence base are real and should be stated plainly. The overwhelming majority of mechanistic data comes from cell culture and animal studies. Human clinical trials are limited largely to topical applications for skin and hair, and even these are often small, short-duration, and industry-sponsored. The absence of large Phase II or Phase III randomised controlled trials for injectable GHK-Cu in humans means that claims about systemic neuroregeneration, organ protection, or epigenetic resetting in people remain scientifically promising but not clinically proven. Clinicians and patients operating in the longevity space must hold both of these realities simultaneously: remarkable preclinical evidence, unresolved clinical confirmation.

For those considering GHK-Cu as part of a broader longevity protocol, the conversation belongs within a clinical framework. The Longevity Optimization programme provides the kind of personalised, evidence-based supervision that contextualises peptide therapy within a patient's full biological picture, rather than treating it as an isolated supplement.

Practical Implications: Where GHK-Cu Fits in a Longevity Protocol

Situating GHK-Cu within a comprehensive longevity strategy requires clarity about what it offers and what it does not replace. For skin health and wound healing, the topical evidence is strong enough to justify clinical use with reasonable confidence, particularly for photoaged skin, chronic wound management, and hair loss as an adjunct to established treatments. Topical formulations are widely available, well-tolerated, and supported by the most robust human data in GHK-Cu's research portfolio.

For systemic effects via injection, the appropriate framing is informed use within a monitored clinical protocol, acknowledging that the full human evidence base is still being built. The mechanistic rationale for neuroregeneration, anti-inflammatory gene modulation, and organ protection is compelling and grounded in real molecular biology, not speculative extrapolation. The compounds that currently sit at the intersection of longevity pharmacology and robust human evidence (metformin, rapamycin, GLP-1 agonists) took decades of clinical investigation to reach their current status. GHK-Cu is earlier in that journey.

GHK-Cu may complement other longevity interventions through complementary or additive mechanisms. Its anti-inflammatory effects align with those of Low Dose Naltrexone (LDN), which modulates immune signalling through distinct opioid receptor pathways. Its antioxidant and mitochondrial support properties are synergistic with compounds targeting cellular energy metabolism. Its DNA repair gene activation is conceptually aligned with interventions targeting senescent cell accumulation. In each case, the combination logic should be assessed clinically, with attention to the individual patient's biological profile, existing protocol, and monitored response.

What GHK-Cu is not is a standalone solution to biological ageing. It is one signal molecule among a complex biological conversation, and its effects depend on the cellular and systemic context in which it operates. In a body where inflammation is poorly controlled, where sleep is inadequate, and where metabolic health is compromised, GHK-Cu is working against a powerful headwind. Foundational health remains the substrate on which peptide interventions build.

Conclusion: A Molecule Ahead of Its Clinical Trials

GHK-Cu is, in a meaningful sense, a molecule that has outrun its clinical evidence. The biology is rich, the mechanisms are specific and plausible, and the preclinical data across wound healing, neuroregeneration, anti-inflammatory signalling, collagen synthesis, and hair growth form a coherent and mutually reinforcing picture. The human clinical evidence, while compelling for topical applications, has not yet caught up with the systemic promise suggested by decades of molecular research.

That gap is not a reason for dismissal. It is a reason for intellectual honesty and clinical rigour. The same precision that makes GHK-Cu biologically interesting, its ability to modulate thousands of genes in directions that resemble biological youth, also demands careful, monitored application rather than casual self-administration. The age-related decline in endogenous GHK-Cu levels is real and correlates with measurable deterioration in tissue repair capacity. Whether restoring those levels through exogenous administration can durably slow or partially reverse those changes in humans is a question that the next decade of clinical research will answer.

For now, the evidence positions GHK-Cu as one of the most biologically sophisticated molecules in the longevity peptide toolkit, distinguished by its breadth of action, its safety profile, and its mechanistic grounding in real human biology. That distinction is earned, not conferred.